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budesonide to control mild to moderate asthma 
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Canada 
The aim of this study was to compare the efficacy, compliance and side-effects of budesonide administered 
twice daily (b.d.) and four times a day (q.d.) with a Turbuhaler @ device in asthmatic subjects requiring 
I 1200 ,ug daily. The randomized, parallel group study design included a 2-week baseline period followed by 
a 612-month treatment period. Subjects were assessed at regular intervals in hospital through FEV,, PC,, 
methacholine, adrenal function and throat swabs. They were asked to record their symptoms and PEF values 
morning and evening at home. An asthmatic flare-up, which was the main outcome resulting in a patient’s 
termination of the study, was defined beforehand as (a) 25% or greater diurnal variability in PEF for 2 
consecutive days, and/or (b) nocturnal awakenings due to asthma symptoms 2 days or more in the same week 
and/or (c) an increase (doubling or more) in the need for inhaled bronchodilator 2 days in the same week. 
Fifty-eight adult asthmatic subjects (20 males and 38 females) entered the study, one-half being randomly 
assigned to the b.d. regimen and one-half to the q.d. regimen. Fourteen subjects were on 40O,~g, 15 subjects 
on 800,~g and 29 subjects on 12OOpg of budesonide daily. Seventeen flare-ups were recorded in the b.d. 
regimen group as opposed to 11 in the q.d. regimen (P=O.O5), significant differences being found in the 800 
and 12OOpg groups (a total of 13 flare-ups in the b.d. group and eight flare-ups in the q.d. group for the two 
doses, P=O.Ol). Kaplan-Meier survival analysis yielded similar results. There was no significant difference in 
FEV,, PC,, or cortisol levels during the study on either regimen. Throat symptoms and growth of Candida 
albicans were more common in the q.d. group. Compliance assessed by the number of times the Turbuhaler@ 
device was actuated was significantly better in the b.d. group (95%) as compared with the q.d. group (83%). 
To conclude, administering inhaled budesonide with a Turbuhaler @ device on a q.d. basis results in fewer 
flare-ups in spite of less satisfactory compliance and more common, local side-effects than on a b.d. regimen 
at daily doses of 800 and 12OOpg. 
Introduction 
Anti-inflammatory medication is currently the cor- 
nerstone in the treatment of asthma (1). In adults, 
inhaled steroids is the preferred anti-inflammatory 
medication. Their use is advocated in international 
guidelines whenever inhaled &-adrenergic agents are 
used on a regular basis (2,3). Although the conven- 
tional dose frequency is four times a day (q.d.), dose 
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frequency is often reduced in an attempt to improve 
patient compliance while maintaining the efficacy of 
the drug. A previous study showed that budesonide, 
administered with a conventional metered dose 
inhaler device, was more efficient when administered 
on a q.d. basis as opposed to a twicedaily (b.d.) basis 
(4). However, one-half of the 36 patients who com- 
pleted the study were on high doses of budesonide 
(1600 pug day - ‘) and it was unknown whether the 
results would hold if budesonide was administered 
in powder form. Inhaled &adrenergic agents and 
anti-inflammatory preparations are now available in 
powder form. The advantages were summarized 
recently (5). Budesonide has been made available in 
0 1995 W. B. Saunders Company Ltd 
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powder form. The Turbuhaler@ is a multiple-dose 
powder inhaler that is easier to use than the standard 
metered dose inhaler (6). 
This study was designed in an attempt to test the 
hypothesis that inhaled budesonide given at daily 
doses 5 1200 ,ug day - ’ would show greater efficacy 
in the context of a q.d. regimen, and that there would 
be equivalent side-effects but better compliance with 
a b.d. regimen. 
Materials and Methods 
SUBJECTS 
Fifty-four adult subjects who fulfilled the criteria 
of the American Thoracic Society for a diagnosis of 
asthma were included in the study (7). Four subjects 
were randomized twice, once in each of the two 
regimens (see below) after a 3-month washout period. 
All were in a clinically steady state (no nocturnal 
awakenings due to asthma, no recent modification in 
their need for bronchodilators) at the time they 
entered into the study. All showed a 2 20% improve- 
ment in FEV, 30 min after inhalation of 0.5 mg 
terbutaline sulphate on entry into the trial. Fifty-two 
subjects underwent methacholine inhalation chal- 
lenges and the provocative concentration causing a 
20% fall in FEV, (PC,, was 5 16 mg ml ~ ‘, indicat- 
ing significant bronchial hyper-responsiveness (8) in 
all of them. None had required oral steroids in the 
3 months preceding the study and none had been 
hospitalized for asthma in the previous year. All gave 
informed written consent and the protocol was 
approved by the Ethics Committee of the Hospital. 
STUDY DESIGN 
The study was of a randomized, open-label, par- 
allel design consisting of a 2-week baseline period 
followed by a 612-month treatment period. After 
the 2-week run-in period in which a clinically stable 
asthmatic state was ensured (no nocturnal awaken- 
ings due to asthma; no recent modification in the 
need for bronchodilators or inhaled steroids, no viral 
infections), eligible patients were randomly assigned 
to receive b.d. dosing with budesonide TurbuhalerB 
or q.d. dosing with budesonide Turbuhaler@, at a 
dose considered to be equivalent to their usual dose 
of inhaled steroids (equivalent doses of 400, 800 or 
12OOpg of budesonide). Subjects on 4OOpg daily 
had to take either 200,~~g b.d. or lOOpug q.d. from 
one of the two different inhalers (one containing 
100,LLgpuff-’ and the other, 200,ug puff ~ I), those 
on 800 ,ug were asked to take 4OOpg b.d. or 2OOpg 
q.d., and, finally, those on 12OOpg, 3 puffs of 2OOpg 
b.d. or 3 puffs of lOOpug q.d. The study was an 
open-label design; however, patients were random- 
ized to treatment by a nurse not involved in the study 
to prevent possible bias in treatment assignment. In 
addition, this nurse was responsible for dispensing 
and collecting all study medications. Patients were 
advised not to discuss their treatment assignment 
with the study personnel. So, every attempt was made 
to keep the study single-blind, despite being open- 
label. Patients were also not informed that their 
compliance was being monitored, so this aspect of the 
study was also single-blind, albeit open-label. An 
open-label design was chosen in order to assess 
patient compliance with the two dosing regimens 
more accurately. Using a double-blind design would 
have meant inconveniencing the patients whether 
they were on a b.d. or q.d. regimen, since they would 
then have had to use two separate inhalers - one q.d. 
and one b.d. With such a study design, it would have 
been impossible to properly evaluate if subjects were 
more compliant with one or other of the dosing 
regimens. A difference in the degree of compliance 
with the two dosing regimens could also have had 
considerable impact on the overall efficacy of the 
dosing regimens. 
Subjects were instructed on how to use the 
Turbuhaler@ with a deep inspiration, not too slow as 
to generate a sufficient flow rate (>30 1 min ~ ‘), and 
a post-inspiratory breath-hold of 10 s. They were 
advised to wash their mouth after using the device. 
Suggested timings for taking the medication were on 
awakening, at noon and supper time, and before 
going to bed. The instructions were similar in the two 
treatment groups and subjects were reminded at each 
visit. Subjects were followed for 6 months (n=8) or 
12 months (n= 18) if they experienced no flare-ups. 
Clinical assessments were completed at weeks 2, 4, 8, 
12, 16, 20, 24 (this was the final visit for subjects who 
decided not to continue with the study because they 
were no longer interested), 30, 36, 42 and 48 weeks. 
At each visit, spirometry was performed, and throat 
swabs for Candida albicans were taken every second 
visit. Assessment of bronchial responsiveness to 
methacholine as well as serum cortisol levels and 
response to an injection of 25 IU synthetic ACTH 
were performed on entry and at the end of the study 
period. Subjects were asked to fill in daily diary cards 
throughout the study, answering the following 
questions: 
(1) Did you have asthma during the . . day/night? 
(2) If asthma was present at night, how many times 
were you awakened by it? 
(3) If asthma was present at night, did you need an 
inhaled &adrenergic agent? 
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(4) 
(5) 
(6) 
(7) 
During the day, how severe was the asthma? 
(answer on a seven-mark scale from absence of 
symptoms to symptoms so severe that the subject 
could not go to work or perform normal daily 
activities) 
Did you cough during the . . . day/night? 
Was your throat sore or hoarse today (answer on 
a four-mark scale) 
How many puffs of inhaled &adrenergic agents 
and inhalations of study medication did you 
take? 
Peak expiratory flow rates (PEF) were recorded 
b.d., upon awakening and at bedtime, before any 
medication scheduled for that time was taken. Sub- 
jects were asked to take three readings and record 
them in their diaries. 
TESTING 
Spirometry was assessed according to American 
Thoracic Society standards (7). The best of two 
reproducible ( f 20 1 min - ‘) PEF values was kept for 
analysis. Bronchial responsiveness to methacholine 
was assessed using Cockcroft et al’s method at tidal 
volume breathing for 2 min with a Wright’s nebulizer 
(output=0.14 ml min- ‘) (9). Throat swabs were 
cultured for Candida, using commercially prepared 
Sabouraud’s and Dextrose Agar plates as the 
medium for yeast growth. Blood was taken for 
cortisol at the same time of day (morning) for each 
patient, and 30 min after the injection of synthetic 
ACTH. 
ANALYSIS OF RESULTS 
An asthmatic flare-up, which was the main out- 
come that resulted in the termination of the study, 
was defined beforehand as: (a) 25% or more changes 
in morning and/or evening PEF values over 2 con- 
secutive days, and/or (b) nocturnal awakenings due 
to asthma symptoms 2 days in the same week, and/or 
(c) an increase (doubling or more) in the need for 
inhaled bronchodilators 2 days in the same week. 
Compliance was measured by continuing to turn 
the dosing grip of the used, returned Turbuhaler@ 
devices until the last dose had been selected. By 
counting the remaining doses and subtracting this 
number from 200 (the total number of doses in 
Turbuhaler@), the number of doses taken by the 
patient was calculated. Patients were not informed 
that their compliance was being monitored.. 
The confidence interval test, X2-test, unpaired 
t-test, analysis of variance with orthogonal contrasts, 
and Kaplan-Meier survival curve were used in the 
analysis of results, with the SYSTAT statistical 
Table 1 Reasons for flare-ups in the b.d. and q.d. groups 
b.d. group q.d. group 
1. Fall in PEF>25% on 2 days 3 1 
2. Nocturnal awakening on 2 days 5 2 
3. Increase in the need for inhaled 
&adrenergic agent on 2 days 4 2 
Combination of criteria 
1+2 0 2 
2+3 3 4 
1+3 2 0 
Total 17 11 
package (SYSTAT, Inc., Evanston, IL). A P value 
5 0.05 was considered significant. 
Results 
Of the 58 subjects, 20 were male and 39 female. 
One-half of the subjects were randomized to the b.d. 
regimen and one-half to the q.d. regimen. Four of the 
58 subjects participated in the study twice, being 
included in the b.d. and the q.d. groups after a 
washout period of 3 months. The mean age 
was 50 & 13 (SD) years. The duration of asthma was 
18 & 17 (SD) years. The mean baseline FEV, was 
75 f 16 (SD) %predicted. There were no significant 
differences in the clinical (number of days with 
asthmatic symptoms), physiological (serial PEF, 
FEV,, PC,,) or laboratory (oral candidiasis, cortisol 
level results) when comparing the b.d. and the q.d. 
groups on entry to the trial and during the baseline 
period, except for the frequency of throat symptoms. 
This was higher in those who later entered in the b.d. 
group (37.2% of days with throat symptoms) in 
comparison with the q.d. group (20.9% of days with 
throat symptoms) k2=28, P<O.OOl). 
Four subjects (one in the b.d. group and three in 
the q.d. group) were excluded after being entered into 
the study because of poor compliance in terms of 
hospital visits. There were four flare-ups in the 400 pg 
b.d. group and three flare-ups in the q.d. group, four 
flare-ups in the 800 pug b.d. group and two flare-ups in 
the q.d. group, and nine flare-ups in the 1200 pug b.d. 
group and six flare-ups in the q.d. group. The number 
of flare-ups was therefore slightly but significantly 
greater in the b.d. group (n=17) than in the q.d. 
group (n= 11) (confidence interval test, P=O.O5). This 
difference was more marked taking into consider- 
ation subjects on the 800 and 12OOpg daily doses (13 
as opposed to 8) (confidence interval test, P=O.Ol). 
The reasons for the flare-ups are listed in Table 1. 
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Fig. I Curves relating time in days to the proportion of 
subjects who did not have a flare-up (a) for all subjects, 
n=58; (b) for subjects on 800 and 12OOpg day- ‘, n=44. 
Curves were analysed by survival analysis and showed a 
borderline difference for the whole group but definite differ- 
ences for subjects on 800 and 1200,~g of budesonide day-’ 
(see text for details of Kaplan-Meier survival analysis). 
Each point represents the time interval at which the cumu- 
lative proportion surviving at end (as obtained from 
the survival analysis) changed. 0, q.d. regimen; 0, b.d. 
regimen. 
Clinical symptoms (nocturnal awakenings due to 
asthma and/or increase in the need for inhaled 
&adrenergic agents) were more often responsible for 
flare-ups than were significant changes in PEF. 
Curves relating the proportion of subjects not 
affected by flare-ups and time from entry in the 
trial are shown in Fig. 1. Survival analysis showed 
borderline differences in the q.d. and b.d. curves 
(Mantel, P=O.15, Breslow-Gehan, P=O.O7, Tarone- 
Ware, P=O.l) when all subjects were included, 
whereas it reached statistical significance when 
analysing the 44 subjects taking 800 and 1200,~g 
of budesonide (Mantel, P=O.O3, Breslow-Gehan, 
PzO.02, Tarone-Ware, PxO.02). Approximately 
one-half of the flare-ups in the b.d. group occurred 
within 1 month of entry into the study. There were no 
significant differences in terms of age, atopic status, 
sex and duration of asthma in those who had early 
flare-ups (in the first 2.5 months after entry), those 
with flare-ups at a later stage and those who had no 
flare-up. Four subjects were included in the b.d. and 
q.d. regimens in order to balance the number in each 
group. Even after eliminating those four subjects, the 
survival analysis remained significant for the 8OOpg 
and 12OOpg groups (Mantel, P=O.O5, Breslow- 
Gehan, PzO.04, Tarone-Ware, P=O.O5) and border- 
line for the whole group (P=O.l). Table 2 shows the 
differences in clinical and functional results between 
the two groups. Although the number of nights with 
awakenings due to asthma and the total number of 
awakenings were significantly more frequent in the 
b.d. group, the number of days with asthmatic symp- 
toms only tended to be significantly greater in the 
same group although the number of days in which a 
&adrenergic agent was used was similar in the two 
groups. Morning (and to a lesser extent, evening) 
PEF values were higher in the q.d. group, and there 
were many fewer days with significant (>25% or 
220%) fluctuations. FEV, and PC,, values were not 
significantly different from the beginning to the end 
of the study. 
Throat symptoms were more common and oral 
candidiasis was more than twice as common in the 
q.d. group (Table 2), although an equivalent number 
of subjects had candidiasis at one time or another 
during the study (five subjects in the b.d. group and 
six subjects in the q.d. group). Cortisol level and the 
response to cortisol after synthetic ACTH injection 
remained unchanged throughout the trial. 
Compliance was significantly better in the b.d. 
group as compared to q.d. group (83 f 16% in the 
q.d. group and 95 & 16% in the b.d. group, P=O.O06). 
Discussion 
This siudy shows that administering budesonide 
on a q.d. basis instead of a b.d. basis has the 
advantage of controlling asthma better at the expense 
of more local (throat) side-effects in subjects who 
require a low to moderate dose of the preparation. A 
previous study at our centre showed that a q.d. 
regimen was superior to a b.d. regimen in terms of 
relapses and several clinical and functional indices 
(4). However, that study (4) (a) included 18 of a total 
of 36 subjects (50%) who were on 1600,~~g of budes- 
onide, which can be considered a high dose, (b) tested 
budesonide with the standard metered dose inhaler 
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Table 2 Comparison of clinical and functional results and side-effects according to regimen 
b.d. group q.d. group x’ P value 
Number of nights with awakenings due to asthma 
(% of total number of nights in the study) 
Number of awakenings due to asthma 
(% of total number of nights in the study) 
Number of days in which &adrenergic agent was used 
(% of total number of days in the study) 
Number of days with asthmatic symptoms 
(% of total number of days in the study) 
Peak flow rates 
Morning value 
(1 min - ‘) 
Mean within-subject variability (SD) 
Evening value 
(1 min - ‘) 
Mean within-subject variability (SD) 
Daily fluctuations 
(maximum-minimum values in % of maximum) 
Number of days with daily fluctuations 
2 25% 
(% of total numbers of days in the study) 
2 20% 
(% of total number of days in the study) 
FEV, 
End of the study (% predicted) 
Changes (% value at entry into the study) 
PC20 
End of the study (mg ml - ‘) 
Changes (number of subjects >2-fold) 
Number of days with throat symptoms 
Oral Candidiasis 
(number of positive/total throat swabs, %) 
Cortisol level 
End of the study (nmol l- ‘) 
Changes (% value at entry into the study) 
,CZ8%, 
(0?9%) 
189 
(0.3%) 
1392 
(23.6%) 
396 (k97) 
23 (+ 12) 
411 (*91) 
20 (*8) 
3.8 (LIZ 9.5) 
438 
(7.4%) 
490 
(8.3%) 
76 ( f 17) 
4.5 ( l 2.2) 
1.9 
8 
938 
(15.9%) 
518 1 
(6.2%) 
309 (A 151) 
- 63 ( f 94) 
(Z3%) 
(0?5%) 
175 
(0.3%) 
1318 
(22.2%) 
423 ( f 97) ’ 
21 (*9) 
434 ( f 90) 
20 (4 7) 
3.1 (*6.8) 
273 
(4.6%) 
362 
(6.1%) 
75 (f 15) 
4.8 ( f 2.3) 
2.5 
8 
1570 
(26.5%) 
13185 
(15.3%) 
290 (k 196) 
3.7 (f 170) 
10.4 
5.4 
0.6 
3.05 
t value 
1.0 
0.7 
1.0 
0 
0.3 
x’ 
42 
21 
I value 
0.2 
0.5 
0.7 
2 
:1 
t value 
198 
3.6 
0.4 
1.9 
0.001 
0.02 
ns 
0.09 
P value 
ns 
ns 
ns 
ns 
ns 
P value 
<O.OOl 
co.001 
P value 
ns 
ns 
ns 
P value 
ns 
P value 
<O.OOl 
0.05 
ns 
ns 
The total number of nights/days was 5899 in the b.d. group and 5928 in the q.d. group. Mean & SD value are given. ns, not 
significant. 
while budesonide is now available in powder form regimen may be just as good as a q.d. regimen in 
and (c) did not assess compliance. subjects taking small doses of inhaled steroids. Most 
The difference in the number of flare-ups was studies that have used small doses of budesonide or 
significant in the 800 and 1200,~g groups but not beclomethasone failed to demonstrate any difference 
among subjects taking 400 pg. In the 800,~g group in efficacy of a b.d. or q.d. regimen. Meltzer et al. 
(15 subjects), four of six subjects (67%) on the b.d. showed no difference when comparing b.d. and q.d. 
regimen experienced flare-ups as compared with only regimens in a group of 52 children and 37 young 
two subjects out of nine (22%) in the q.d. regimen adults who required 336,ug of beclomethasone daily, 
group. In the 400,ug group which included 14 which is comparable to 400,ug dose of budesonide 
subjects, it was not possible to document superior (10). Nyholm et al. also failed to demonstrate the 
efficacy of the q.d. regimen over the b.d. regimen. superior efficacy of a q.d. regimen in 24 adults who 
Although the possibility that there would have been were on a daily dose of 400 pg of budesonide (11). 
differences if a larger number of subjects had been Field et al. showed that 400 lug of budesonide admin- 
included cannot be excluded, this suggests that a b.d. istered b.d. (200,~g each time) had the same efficacy 
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as beclomethasone administered q.d. (100 pug each 
time) (12). Willey et al. had similar results in 30 adult 
patients using a similar design (13). Toogood et al. 
found advantages in using the q.d. regimen over the 
b.d. regimen in 37 subjects who were given 400, 800 
and 1600,ug of budesonide, although the dose by 
itself was the major determinant of efficacy (14). The 
inclusion of clinically unstable subjects (pollen 
sensitive patients studied during the pollen season) 
in the study by Toogood et al. could have enhanced 
the potential difference in efficacy (14). Dahl and 
Johansson also found advantage in terms of PEF 
values but not in terms of clinical efficacy in using 
a q.d. as opposed to a b.d. regimen (15). However, 
this included patients taking 400 and 8OOpg of 
budesonide daily. The authors did not mention if 
these differences hold for both the 400 and 800,~~g 
daily doses. 
In a previous study, the number of relapses was 
found to be equivalent in subjects on a high dose of 
budesonide (1660 pg), regardless of the regimen (b.d. 
or q.d.) (4). This was explained by the fact that 
one-half of the subjects were on oral steroids as well, 
which could have masked the difference. Satisfactory 
control of asthma was also more difficult in this 
group, which could explain why it was impossible to 
detect differences. The evidence, therefore, is that in 
the low (400,~g) and high (16OOpg) dose ranges, 
administering budesonide on a b.d. or a q.d. regimen 
results in no significant influence on its efficacy. 
Differences can only be detected in the middle dose 
range (800 and 1200,~g daily). 
Although the efficacy of budesonide was better in 
the q.d. group, throat symptoms and the proportion 
of positive throat swabs for Candida albicans were 
also higher, a difference from a previous study (4). 
However, Toogood et al. also found that the fre- 
quency of oropharyngeal candidiasis correlated 
strongly with the daily dose of budesonide and 
dosing frequency, a b.d. treatment abolishing the 
effect of increasing the dose of budesonide on 
candidiasis (16). This different type of comparison 
(graded dose) used by Toogood et al. (14) indicated 
that (a) to achieve equivalent levels of anti-asthmatic 
response, a higher and more toxic dose of budesonide 
is required if the total daily dose is administered in 
two rather than four divided doses, (b) that the 
difference is potentially clinically important, i.e. to 
achieve an equivalent anti-asthmatic response, a low 
and non-toxic dosage would have to be increased to 
high and potentially toxic levels (17) and (c) the 
difference may only be demonstrable when the 
asthma has been destabilized immediately prior 
to making the comparison. Adrenal function as 
assessed by cortisol levels before and after adminis- 
tering synthetic ACTH was equivalent in the two 
groups. 
Although the q.d. regimen was more effective than 
the b.d. regimen in the 800 and 12OOpg range doses, 
compliance was significantly better in the b.d.group, 
as expected. Compliance was assessed in an indirect 
way by counting the number of puffs which were not 
actuated. No direct and more precise means to assess 
timing of actuation and whether patients really took 
the inhalation was available. The statistically signifi- 
cant difference in compliance which favoured the b.d. 
over the q.d. regimen proved clinically inconsequen- 
tial since it was more than offset by the potency- 
reducing effect of b.d. treatment. The fact that 
compliance was on the whole very good, even in the 
q.d. group, can be explained by the fact that more 
compliant subjects are more likely to be included in 
clinical trials. This is also reflected by the fact that 
only four subjects had to be withdrawn due to poor 
compliance in terms of hospital appointments. 
To conclude, the efficacy of budesonide adminis- 
tered with a Turbuhalera device is better when 
administered on a q.d. basis than on a b.d. regimen. 
Although compliance was less satisfactory, a differ- 
ence in efficacy favouring the q.d. regimen was 
detected. These results hold for the moderate daily 
doses of 800 and 12OOpg. Although efficacy was 
better in the q.d. group, this was at the expense of 
more local side-effects in terms of throat symptoms 
(16% as opposed to 27% of days) and growth of 
Candida albicans. Advising patients to take their 
medication on a q.d. basis is valuable in terms of 
better efficacy but one should expect less compliance 
and more throat side-effects. It would appear to us 
particularly relevant to recommend a q.d. regimen in 
those requiring 800,~g or more of budesonide, con- 
sidering that this dose can lead to some systemic 
absorption. 
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